+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir



Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir



Journal of Acquired Immune Deficiency Syndromes 31(4): 399-403



Objective: To assess and compare the activity and safety of capsules containing enteric-coated beadlets of didanosine given once daily with stavudine and nelfinavir with that of a standard reference triple drug regimen of zidovudine plus lamivudine and nelfinavir. Design: Multinational, 49-site, prospective, open-label, randomized, two-arm comparison study. Participants: HIV-infected subjects with limited or no previous antiretroviral therapy who had plasma HIV RNA levels of gtoreq2000 copies/mL and CD4 cell counts of gtoreq200/mm3 (511 were randomized to treatment groups, and 352 completed the study). Interventions: Triple antiretroviral therapy for 48 weeks: didanosine EC (400 mg once daily), stavudine (40 mg twice daily), and nelfinavir (750 mg three times daily) or a twice-daily coformulation of zidovudine (300 mg) plus lamivudine (150 mg) and nelfinavir (750 mg three times daily). Main Outcome Measure: Proportion of subjects with HIV RNA levels of <400 copies/mL at week 48 based on an "intent-to-treat, missing = treatment failure" analysis. Results: The two treatment groups were similar in the proportion of treatment responders (i.e., HIV RNA level of <400 copies/mL), with 54% of subjects in the didanosine EC and zidovudine plus lamivudine treatment groups responding at week 48. Results of other analyses supported those of the primary analysis. The two study regimens were associated with similar numbers of adverse events. Conclusions: The antiviral efficacy of a triple combination regimen containing once-daily didanosine EC is similar to that of a reference triple combination regimen.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010191250

Download citation: RISBibTeXText

PMID: 12447010

DOI: 10.1097/00126334-200212010-00005


Related references

Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in antiretroviral naive HIV patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 261, 2002

Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir. Antiviral Therapy 3(Suppl. 4): 63-64, 1998

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection. Clinical Therapeutics 21(11): 1853-1863, 1999

A pilot study of safety and antiviral activity of the combination of stavudine, didanosine and nelfinavir in HIV-infected subjects. AIDS (London) 10(Suppl. 2): S17, 1996

Correlation of efficacy, nelfinavir pharmacokinetics and diarrhea in treatment-naive HIV positive patients receiving nelfinavir, zidovudine and lamivudine. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 330, 2001

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antiviral Therapy 8(2): 163-171, 2003

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Medicine 7(2): 85-98, 2006

Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. Journal of Infectious Diseases 182(2): 420-427, 2000

AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antiviral Therapy 6(2): 127-134, 2001

Antiviral efficacy of twice daily RESCRIPTOR plus nelfinavir , didanosine , and stavudine in triple and quadruple treatment regimens. AIDS 12(Suppl. 4): S36, 1998

Antiviral effect of increasing nelfinavir concentrations using delavirdine in combination with didanosine and stavudine is maintained through 48 weeks of therapy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 520, 1999

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Journal of Infectious Diseases 189(1): 51-60, 2004

Safety and pharmacokinetics of stavudine and didanosine when co-administered with nelfinavir in HIV-exposed neonates. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 332, 2001

The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children. Southeast Asian Journal of Tropical Medicine and Public Health 33(2): 280-287, 2002

Rapid viral load reduction with a regimen of nelfinavir, stavudine, didanosine, and hydroxyurea. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 442, 1998